Docoh
Loading...

VCYT Veracyte

News

From Benzinga Pro
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Dec. 3, 2021: DOCU, ZM, TRMB, DNA, MTLS, VCYT, SGFY, SSYS, BLDE, MKFG, ACHR, TWLO, U, SPLK, RBLX, PD, CND, SLGC, MASS, QSI
6 Dec 21
Hedge Funds, Trading Ideas, General
DOCUSIGN INC (DOCU) - 746964 ZOOM VIDEO COMMUNICATIONS INC (ZM) - 223111 TRIMBLE INC (TRMB) - 75800 GINKGO BIOWORKS HOLDINGS INC (DNA) - 1679456 MATERIALISE NV (MTLS) - 42598 VERACYTE INC (VCYT) - 43000 SIGNIFY
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Dec. 1, 2021: ZM, TRMB, TWLO, DNA, MTLS, SGFY, NTLA, BLDE, ACHR, MKFG, ONEM, VCYT, SDGR, SURF, MASS, SLGC, SE, TOST, VLD
2 Dec 21
Hedge Funds, Trading Ideas, General
ZOOM VIDEO COMMUNICATIONS INC (ZM) - 165622 TRIMBLE INC (TRMB) - 251411 TWILIO INC (TWLO) - 92701 GINKGO BIOWORKS HOLDINGS INC (DNA) - 1480325 MATERIALISE NV (MTLS) - 45325 SIGNIFY HEALTH INC (SGFY) -
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Nov. 30, 2021: ZM, TWTR, HOOD, TRMB, PACB, SGFY, MTLS, VLD, BLDE, MKFG, ACHR, ZM, CND, VCYT, ONEM, SDGR, NTLA, DNA, SLGC, MASS, ARCT, SURF, TOST, IRDM
1 Dec 21
Hedge Funds, Trading Ideas, General
ZOOM VIDEO COMMUNICATIONS INC (ZM) - 161827 TWITTER INC (TWTR) - 1112372 ROBINHOOD MARKETS INC (HOOD) - 837248 TRIMBLE INC (TRMB) - 206000 PACIFIC BIOSCIENCES OF CALIFORNIA INC (PACB) - 161674 SIGNIFY HEALTH INC
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
16 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) 2U (TWOU) Veracyte (VCYT) Beam Therapeutics (BEAM) Materialise (MTLS) Proto Labs (PRLB) TuSimple Holdings (TSP) Archer Aviation (ACHR) Velo3d (VLD) Splunk (SPLK) The Walt Disney
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Nov. 12, 2021: SGFY, VCYT, MTLS, BLDE, VERV, ALLO, QSI
15 Nov 21
Hedge Funds, Trading Ideas, General
Signify Health (SGFY) Veracyte (VCYT) Materialise (MTLS) Blade Air Mobility (BLDE) Verve Therapeutics (VERV) Allogene Biotherapeutics (ALLO) Quantum-Si (QSI)
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Nov. 10 2021: PLTR, VCYT, MTLS, VLD, MKFG, ALLO, NTLA, VERV, TOST
11 Nov 21
News, Hedge Funds, Trading Ideas, General
Palantir (PLTR) Veracyte (VCYT) Materialise (MTLS) Velo3D (VLD) Markforged (MKFG) Allogene (ALLO) Intellia Therapeutics (NTLA) Verve Therapeutics (VERV) Toast (TOST)
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Nov. 9, 2021: PLTR, PACB, NVTA, VCYT, EXAS, MTLS, DDD, MKFG, HOOD, ADPT, ALLO, VERV
10 Nov 21
Hedge Funds, Trading Ideas, General
Palantir Technologies (PLTR) Pacific Biosciences of California (PACB) Invitae (NVTA) Veracyte (VCYT) Exact Sciences (EXAS) Materialise (MTLS) 3D Systems (DDD) Markforged Holding (MKFG) Robinhood Markets
Raymond James Maintains Outperform on Veracyte, Raises Price Target to $62
10 Nov 21
News, Price Target, Analyst Ratings
Raymond James analyst Andrew Cooper maintains Veracyte (NASDAQ:VCYT) with a Outperform and raises the price target from $50 to $62.
Veracyte Q3 EPS $(0.20) Misses $(0.16) Estimate, Sales $60.37M Beat $54.38M Estimate
9 Nov 21
Earnings, News
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.16) by 25 percent. This is a 150 percent decrease over losses of $(0.08) per share from the same
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
9 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
9 Nov 21
Earnings, M&A, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
Veracyte Announces Immunoscore Colon Cancer Test Included In ESMO Clinical Practice Guidelines Adapted For Pan-Asia
5 Nov 21
News, FDA
Veracyte, Inc. (NASDAQ:VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Oct. 25, 2021: TWTR, ROKU, PACB, BEAM, NNDM, SNAP, LPSN, SPOT, SKLZ, PD, ARCT, SLGC, NTLA, VERV, VCYT, PATH, DKNG, HOOD, AMZN, ETSY, PAGS, MKFG, DDD, BLDE, VLD
26 Oct 21
Hedge Funds, Trading Ideas, General
Twitter (TWTR) - 103,155 Roku (ROKU) - 12,731 Pacific Biosceiences of California (PACB) - 78,058 Beam Therapeutics (BEAM) - 7,638 Nano Dimension (NNDM)
Veracyte Highlights Data Presented At ASTRO 2021; Says Data Validate Prognostic Value Of Decipher Prostate Genomic Test In Newly Diagnosed, Clinically High-Risk Prostate Cancer
25 Oct 21
News, FDA, Events
Veracyte, Inc. (NASDAQ:VCYT) announced today that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company's Decipher Prostate genomic classifier
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 22, 2021: TWTR, ROKU, BEAM, NTLA, VLD, SNAP, LPSN, SKLZ, PACB, SLGC, ARCT, VCYT, SURF
25 Oct 21
Hedge Funds, Trading Ideas, General
Twitter (TWTR) - 448,944 Roku (ROKU) - 16,743 Beam Therapeutics (BEAM) - 45,600 Intellia Therapeutics (NTLA) - 27,753 Velo3D (VLD) - 203467 Snap (SNAP)
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Oct. 21, 2021: SKLZ, NTLA, SLGC, PACB, VCYT, ARCT, SURF
22 Oct 21
Hedge Funds, Trading Ideas, General
Skillz (SKLZ) - 2,112,856 Intellia Therapeutics (NTLA) - 28,280 Beam Therapeutics (BEAM) - 14,943 SomaLogic (SLGC) - 225,026 Pacific Biosciences of California (PACB)
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Oct. 18, 2021: NTLA, TDOC, BLDE, VLD, GENI, QSI, SURF, SLGC, VCYT
19 Oct 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 26,537 Teladoc Health (TDOC) - 100 Blade Air Mobility (BLDE) - 156,754 Velo3D (VLD) - 1,200 Genius Sports (GENI) - 42,223 Quantum-Si (QSI)
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 15, 2021: NTLA, TDOC, BLDE, TWOU, VLD, SLGC, VCYT, QSI, MKFG
18 Oct 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 65,996 Teladoc Health (TDOC) - 48,448 Blade Air Mobility (BLDE) - 229,411 2U (TWOU) - 34,575 Velo3D (VLD) - 126,360 SomaLogic
Veracyte Says New Data To Be Presented At ASTRO 2021; Co Says Data Further Validate Clinical Utility Of Veracyte's Decipher Prostate Genomic Classifier
14 Oct 21
News, FDA, Events
Veracyte, Inc. (NASDAQ:VCYT) announced that new data further validating the clinical utility of the company's Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology
Veracyte Highlights New Data Showing Its Envisia Genomic Classifier Impacted Clinical-Decision Making In Idiopathic Pulmonary Fibrosis
11 Oct 21
Biotech, News, FDA, General
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ:VCYT) announced new data demonstrating that the Envisia Genomic Classifier

Press releases

From Benzinga Pro
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
1 Dec 21
Small Cap, Opinion, Press Releases
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Early onset colorectal cancer is currently on the rise [1], according to a new study [2] from the University of Colorado School of Medicine in Denver. The findings come just as the
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
24 Nov 21
Press Releases
Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions Veracyte, Inc. (NASDAQ:VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
13 Nov 21
Press Releases
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics Veracyte, Inc. (NASDAQ:VCYT) today announced that new
Veracyte Announces Third Quarter 2021 Financial Results
9 Nov 21
Press Releases
Total Revenue of $60.4 Million and Volume of 20,972 Tests Company Launches Percepta Nasal Swab and Decipher Bladder Genomic Tests; Completes Acquisition of HalioDx Conference Call and Webcast Today at 4:30 p.m.
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
5 Nov 21
Press Releases
Veracyte, Inc. (NASDAQ:VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
3 Nov 21
Press Releases
Veracyte, Inc. (NASDAQ:VCYT) announced today the publication of new long-term clinical utility data showing that the company's Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company's Immuno-Oncology Capabilities
2 Nov 21
Press Releases
Brightplex technology, acquired from HalioDx, is designed to help drug developers understand and leverage the tumor micro-environment Veracyte, Inc. (NASDAQ:VCYT) today announced that three abstracts highlighting the
New Data Demonstrate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
26 Oct 21
Press Releases
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 Veracyte, Inc. (NASDAQ:VCYT) announced new data demonstrating the clinical utility of the company's Decipher Prostate genomic classifier for
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
25 Oct 21
Press Releases
- First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials - Veracyte, Inc. (NASDAQ:VCYT) announced today that new data being presented at the American Society
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier
14 Oct 21
Press Releases
- Findings from Analysis Evaluating Test In Newly Diagnosed, Clinically High-Risk Disease to be Highlighted in ASTRO Press Program - Veracyte, Inc. (NASDAQ:VCYT) announced that new data further validating the clinical
New Publication Demonstrates Ability of Veracyte's Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
13 Oct 21
Press Releases
Veracyte, Inc., (NASDAQ:VCYT) announced today the publication of new data demonstrating that the company's Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
12 Oct 21
Press Releases
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9. Company management will host a conference call and
New Clinical Utility Data Confirm Veracyte's Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
11 Oct 21
Press Releases
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 Veracyte, Inc. (NASDAQ:VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment
11 Oct 21
Press Releases
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosis Veracyte, Inc. (NASDAQ:VCYT) today announced that new expanded clinical
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte's Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
6 Oct 21
Press Releases
- Expanded clinical validation data demonstrate Percepta Nasal Swab test performance across nodule sizes and cancer stages in early lung cancer assessment - - Findings reinforce value of Percepta GSC and Envisia GC in
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
14 Sep 21
Press Releases
Veracyte, Inc. (NASDAQ:VCYT) today announced that its Decipher® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for